CymaBay Therapeutics Inc. - Common Stock (NQ:CBAY)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Mar 21, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CymaBay Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 Next >

Why CymaBay Therapeutics Stock Is Sinking This Week ↗

September 21, 2023

The stock has given up some of its gains but remains up more than 130% year to date.

Via The Motley Fool

Investors Eye CymaBay's AFFIRM Study As Regulatory Uncertainties Ease ↗

September 21, 2023

Thursday, CymaBay Therapeutics Inc (NASDAQ: CBAY) initiated the AFFIRM Phase 3b/4 confirmatory study to evaluate the effect of seladelpar on clinical outcomes in patients with compensated cirrhosis due...

Via Benzinga

Why CymaBay Therapeutics Stock Triumphed Again on Tuesday ↗

September 12, 2023

The company is about to reap more money than previously expected from a new capital-raising effort.

Via The Motley Fool

Why CymaBay Therapeutics Stock Popped Again Today ↗

September 11, 2023

Days after it reported highly encouraging news from a clinical trial, the company announced a new round of capital-raising.

Via The Motley Fool

Why Hooker Furnishings Are Trading Lower By 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

September 08, 2023

Gainers Biocept, Inc. (NASDAQ: BIOC) shares jumped 97.6% to $1.6608 after the company announced non-exclusive licensing agreement for CNSide with Plus Therapeutics.

Via Benzinga

Analyst Expectations for CymaBay Therapeutics's Future ↗

August 31, 2023

Via Benzinga

Why CymaBay Therapeutics Stock Is Jumping Today ↗

September 08, 2023

The momentum continues after CymaBay reported great clinical results on Thursday.

Via The Motley Fool

Why CymaBay, With 172% Growth This Year, Just Surged For A Second Day Running ↗

September 08, 2023

The company is working on a treatment for a liver disease that can cause severe itching.

Via Investor's Business Daily

Smartsheet, Kroger, Lantronix And Other Big Stocks Moving Higher On Friday ↗

September 08, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Friday. Here are some big stocks recording gains in today’s session. Lantronix, Inc. (NASDAQ: LTRX) shares jumped 26.3% to...

Via Benzinga

Topics Stocks

CymaBay Therapeutics' Lead Drug Candidate Hits Main Goal In Pivotal Study For Liver Damage ↗

September 07, 2023

CymaBay Therapeutics Inc (NASDAQ: CBAY) released topline results from its Phase 3 pivotal RESPONSE study of seladelpar for adult patients with

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

September 07, 2023

Via Benzinga

CymaBay Therapeutics Inc. (NASDAQ: CBAY) Climbs to New 52-Week High

August 11, 2023

Via Investor Brand Network

Earnings Preview For CymaBay Therapeutics ↗

August 09, 2023

Via Benzinga

7 Analysts Have This to Say About CymaBay Therapeutics ↗

July 31, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 14, 2023 ↗

August 14, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 11, 2023 ↗

August 11, 2023

Via Benzinga

CymaBay Therapeutics Inc. (NASDAQ: CBAY) Leading the Way in Friday Trading Based on Percentage Gain

June 30, 2023

Via Investor Brand Network

Why Shares of CymaBay Therapeutics Are Soaring Friday ↗

June 30, 2023

A competitor's drug had a so-so phase 3 trial, lifting the possibilities for CymaBay's lead therapy.

Via The Motley Fool

Analyst Expectations for CymaBay Therapeutics's Future ↗

June 26, 2023

Via Benzinga

Intercept Pharma Gets Double Upgrade: Analyst Says OCA Combo Therapy Can Extend PBC Business ↗

July 13, 2023

HC Wainwright has upgraded Intercept Pharmaceuticals Inc (NASDAQ: ICPT) to Buy from Sell, with a price target of

Via Benzinga

Genfit's Miss Is CymaBay Therapeutics' Gain: Analyst Says Rival Data Leaves Room for Seladelpar To Emerge As Best-In-Class ↗

June 30, 2023

Friday, CymaBay Therapeutics Inc's (NASDAQ: CBAY) competitors Genfit SA (NASDAQ: GNFT) and Ipsen SA (OTC:

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

June 30, 2023

Via Benzinga

Why Cineverse Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

June 30, 2023

Gainers Addentax Group Corp. (NASDAQ: ATXG) shares jumped 47.3% to $9.68. Addentax Group is launching automation of artificial intelligence internet operational tools project with top...

Via Benzinga

Expert Ratings for CymaBay Therapeutics ↗

May 16, 2023

Via Benzinga

Carnival, SMART Global, Friedman Industries And Other Big Stocks Moving Higher On Friday ↗

June 30, 2023

U.S. stocks traded higher, with the Dow Jones gaining more than 200 points on Friday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Dow Surges 200 Points; Constellation Brands Posts Upbeat Results ↗

June 30, 2023

U.S. stocks traded higher this morning, with the Dow Jones gaining more than 200 points on Friday. Following the market opening Friday, the Dow traded up 0.63% to 34,338.23 while the NASDAQ rose 1.05%...

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

June 30, 2023

Via Benzinga

Former Wall Street Darling Intercept Restructures After FDA Rejects Its Liver Drug ↗

June 23, 2023

Following the FDA rejection, Intercept will restructure to focus on rare liver diseases.

Via Investor's Business Daily

What Now After FDA AdComm Rebuke for Intercept Pharmaceutical? Analyst Says Approval Of Intercept's 'OCA In NASH May Never Occur ↗

May 22, 2023

On Friday, FDA's Gastrointestinal Drugs Advisory Committee voted 12 to 2—with two abstentions—that the benefits of Intercept Pharmaceutical Inc's ICPT Ocaliva 25 mg, also known as Obeticholic acid...

Via Benzinga

Why CymaBay Therapeutics Stock Nose-Dived This Week ↗

May 19, 2023

Investors did not warmly greet the latest news from the biotech.

Via The Motley Fool

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.